Pathogen inactivation treatment of plasma and platelet concentrates and their predicted functionality in massive transfusion protocols

Transfusion

Volumn 57, Issue 5, 2017, Pages 1208-1217

  Arbaeen, Ahmad F ^a,c   Schubert, Peter ^a,b   Serrano, Katherine ^a,b   Carter, Cedric J ^a   Culibrk, Brankica ^b   Devine, Dana V ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CANADIAN BLOOD SERVICES   (Canada)

^c UMM AL QURA UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

PADGEM PROTEIN; RIBOFLAVIN; SODIUM CHLORIDE; THROMBOCYTE CONCENTRATE;

ARTICLE; BLOOD CLOTTING PARAMETERS; BLOOD COMPONENT; CLOT FORMING TIME; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FIBRINOLYSIS; HEMATOCRIT; HEMODILUTION; HUMAN; HYPOCOAGULABILITY; IN VITRO STUDY; INJURY; PATHOGENESIS; PH; PLASMA TRANSFUSION; ROTATIONAL THROMBOELASTOMETRY; THROMBOCYTE ACTIVATION; THROMBOCYTE TRANSFUSION; THROMBOELASTOGRAPHY; ULTRAVIOLET RADIATION; ADVERSE EFFECTS; BLOOD COMPONENT THERAPY; DISINFECTION; HEMORRHAGE; HEMOSTATIC TECHNIQUE; PLASMA; PROCEDURES; QUALITY CONTROL; STANDARDS; THROMBOCYTE;

BLOOD COMPONENT TRANSFUSION; BLOOD PLATELETS; DISINFECTION; HEMODILUTION; HEMORRHAGE; HEMOSTATIC TECHNIQUES; HUMANS; PLASMA; QUALITY CONTROL; RIBOFLAVIN; THROMBELASTOGRAPHY; ULTRAVIOLET RAYS;

EID: 85013807573     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.14043     Document Type: Article

References (47)

1. Tisherman SA, Schmicker RH, Brasel KJ, et al. Detailed description of all deaths in both the shock and traumatic brain injury hypertonic saline trials of the Resuscitation Outcomes Consortium. Ann Surg 2015;261:586-90.
2. Rhee P, Joseph B, Pandit V, et al. Increasing trauma deaths in the United States. Ann Surg 2014;260:13-21.
3. Holcomb JB. Optimal use of blood products in severely injured trauma patients. Hematology Am Soc Hematol Educ Program 2010;2010:465-9.
4. Duchesne JC, Barbeau JM, Islam TM, et al. Damage control resuscitation: from emergency department to the operating room. Am Surg 2011;77:201-6.
5. Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA 2015;313:471-82.
6. Holcomb JB, d el Junco DJ, Fox EE, et al. The prospective, observational, multicenter, major trauma transfusion (PROMMTT) study: comparative effectiveness of a time-varying treatment with competing risks. JAMA Surg 2013;148:127-36.
7. Pohlman TH, Walsh M, Aversa J, Hutchison EM, Olsen KP, Lawrence Reed R. Damage control resuscitation. Blood Rev 2015;29:251-62.
8. Lozano M, Cid J. Pathogen inactivation: coming of age. Curr Opin Hematol 2013;20:540-5.
9. Prowse CV. Component pathogen inactivation: a critical review. Vox Sang 2013;104:183-99.
10. Devine DV, Schubert P. Pathogen inactivation technologies: the advent of pathogen-reduced blood components to reduce blood safety risk. Hematol Oncol Clin North Am 2016;30:609-17.
11. Schlenke P. Pathogen inactivation technologies for cellular blood components: an update. Transfus Med Hemother 2014;41:309-25.
12. Cap AP, Pidcoke HF, Keil SD, et al. Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro. Transfusion 2016;56(Suppl 1):S6-S15.
13. Reddy HL, Doane SK, Keil SD, Marschner S, Goodrich RP. Development of a riboflavin and ultraviolet light-based device to treat whole blood. Transfusion 2013;53(Suppl 1):131S-6S.
14. Schubert P, Coupland D, Culibrk B, Goodrich RP, Devine DV. Riboflavin and ultraviolet light treatment of platelets triggers p38MAPK signaling: inhibition significantly improves in vitro platelet quality after pathogen reduction treatment. Transfusion 2013;53:3164-73.
15. Bihm DJ, Ettinger A, Buytaert-Hoefen KA, et al. Characterization of plasma protein activity in riboflavin and UV light-treated fresh frozen plasma during 2 years of storage at −30 degrees C. Vox Sang 2010;98:108-15.
16. Ostrowski SR, Bochsen L, Windeløv NA, et al. Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology. Transfusion 2011;51:344-56.
17. Hess JR, Pagano MB, Barbeau JD, Johansson PI. Will pathogen reduction of blood components harm more people than it helps in developed countries? Transfusion 2016;56:1236-41.
18. Validation Task Force of the International Society of Blood Transfusion Working Party on Information Technology. ISBT guidelines for validation of automated systems in blood establishments. Vox Sang 2010;98(Suppl 1):1–15, 15-9.
19. Maurer-Spurej E, Chipperfield K. Past and future approaches to assess the quality of platelets for transfusion. Transfus Med Rev 2007;21:295-306.
20. Holme S. In vitro assays used in the evaluation of the quality of stored platelets: correlation with in vivo assays. Transfus Apher Sci 2008;39:161-5.
21. Luddington RJ. Thrombelastography/thromboelastometry. Clin Lab Haematol 2005;27:81-90.
22. Johansson PI, Sørensen AM, Larsen CF, et al. Low hemorrhage-related mortality in trauma patients in a level I trauma center employing transfusion packages and early thromboelastography-directed hemostatic resuscitation with plasma and platelets. Transfusion 2013;53:3088-99.
23. Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F, Ergin MA. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999;88:312-9.
24. Agren A, Edgren G, Kardell M, Ostlund A, Wikman AT. In vitro combinations of red blood cell, plasma and platelet components evaluated by thromboelastography. Blood Transfus 2014;12:491-6.
25. Bontekoe IJ, van der Meer PF, de Korte D. Determination of thromboelastographic responsiveness in stored single-donor platelet concentrates. Transfusion 2014;54:1610-8.
26. Arbaeen AF, Serrano K, Levin E et al. Platelet concentrate functionality assessed by thromboelastography or rotational thromboelastometry [published online ahead of print 2016 Aug 16]. Transfusion. doi: 10.1111/trf.13760.
27. Levin E, Culibrk B, Gyöngyössy-Issa MI, et al. Implementation of buffy coat platelet component production: comparison to platelet-rich plasma platelet production. Transfusion 2008;48:2331-7.
28. Levin E, Jenkins C, Culibrk B, Gyöngyössy-Issa MI, Serano K, Devine DV. Development of a quality monitoring program for platelet components: a report of the first four years' experience at Canadian Blood Services. Transfusion 2012;52:810-8.
29. Schubert P, Culibrk B, Coupland D, Levin E, Devine DV. Impact of sample volume and handling time during analysis on the in vitro quality measurements of platelet concentrates held in syringes. Int J Lab Hematol 2011;33:579-85.
30. Johansson PI, Stensballe J, Vindeløv N, Perner A, Espersen K. Hypocoagulability, as evaluated by thrombelastography, at admission to the ICU is associated with increased 30-day mortality. Blood Coagul Fibrinolysis 2010;21:168-74.
31. Snyder E, Raife T, Lin L, et al. Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light. Transfusion 2004;44:1732-40.
32. AuBuchon JP, Herschel L, Roger J, et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005;45:1335-41.
33. Hornsey VS, Drummond O, Morrison A, McMillan L, MacGregor IR, Prowse CV. Pathogen reduction of fresh plasma using riboflavin and ultraviolet light: effects on plasma coagulation proteins. Transfusion 2009;49:2167-72.
34. Larrea L, Calabuig M, Roldán V, et al. The influence of riboflavin photochemistry on plasma coagulation factors. Transfus Apher Sci 2009;41:199-204.
35. Harr JN, Moore EE, Ghasabyan A, et al. Functional fibrinogen assay indicates that fibrinogen is critical in correcting abnormal clot strength following trauma. Shock 2013;39:45-9.
36. Smith J, Rock G. Protein quality in Mirasol pathogen reduction technology-treated, apheresis-derived fresh-frozen plasma. Transfusion 2010;50:926-31.
37. Jámbor C, Reul V, Schnider TW, Degiocomi P, Metzner H, Korte WC. In vitro inhibition of factor XIII retards clot formation, reduces clot firmness, and increases fibrinolytic effects in whole blood. Anesth Analg 2009;109:1023-8.
38. Theusinger OM, Baulig W, Asmis LM, Seifert B, Spahn Dr. In vitro factor XIII supplementation increases clot firmness in rotation thromboelastometry (ROTEM). Thromb Haemost 2010;104:385-91.
39. Benjamin RJ, McLaughlin LS. Plasma components: properties, differences, and uses. Transfusion 2012;52(Suppl 1):9S-19S.
40. Coene J, Devreese K, Sabot B, Feys HB, Vanderkerckhove P, Compernolle V. Paired analysis of plasma proteins and coagulant capacity after treatment with three methods of pathogen reduction. Transfusion 2014;54:1321-31.
41. Mirasol Clinical Evaluation Study Group. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010;50:2362-75.
42. van Rhenen D, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003;101:2426-33.
43. Snyder E, McCullough J, Slichter SJ, et al. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 2005;45:1864-75.
44. Schöchl H, Frietsch T, Pavelka M, Jámbor C. Hyperfibrinolysis after major trauma: differential diagnosis of lysis patterns and prognostic value of thrombelastometry. J Trauma 2009;67:125-31.
45. Kashuk JL, Moore EE, Sawyer M, et al. Primary fibrinolysis is integral in the pathogenesis of the acute coagulopathy of trauma. Ann Surg 2010;252:434-42.
46. CRASH-2 Trial Collaborators, Shakur H, Roberts I, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010;376:23-32.
47. Koch CG, Li L, Duncan AI, et al. Morbidity and mortality risks associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med 2006;34:1608-16.